4.6 Article

Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience

Related references

Note: Only part of the references are listed.
Article Hematology

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study

Hanny Al-Samkari et al.

Summary: This observational study investigated the outcomes of patients with immune thrombocytopenia (ITP) who switched from romiplostim or eltrombopag to avatrombopag. The results showed that avatrombopag was effective in increasing platelet count in the majority of patients, even in those with inadequate response to a prior TPO-RA.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Article Medicine, General & Internal

Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia

Charlotte A. Bradbury et al.

Summary: In a multicenter, open-label, randomized trial on patients with immune thrombocytopenia, 91.5% of patients who received mycophenolate mofetil plus glucocorticoids had platelet levels above 100,000 per microliter, compared to 63.9% of patients who received glucocorticoids only. Quality-of-life measures of physical function and fatigue were worse in the mycophenolate mofetil group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Immunology

Sirolimus versus cyclosporine for the treatment of pediatric chronic immune thrombocytopenia: A randomized blinded trial

Morteza Mousavi-Hasanzadeh et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

Article Hematology

American Society of Hematology 2019 guidelines for immune thrombocytopenia

Cindy Neunert et al.

BLOOD ADVANCES (2019)

Article Medicine, General & Internal

Long-term complications of splenectomy in adult immune thrombocytopenia

Lan-Huong Thai et al.

MEDICINE (2016)

Article Hematology

Mycophenolate mofetil therapy for severe immune thrombocytopenia

Alice Taylor et al.

BRITISH JOURNAL OF HAEMATOLOGY (2015)